The content on this site is intended for healthcare professionals only
Dr Sara Ghorashian talks to ecancer at the ALL Assembly 2018 Meeting in Amsterdam about the challenges and opportunities of using CAR-T cells to treat ALL patients.
Dr Ghorashian outlines the three studies that she presented on this treatment.
She explains that expansion cohorts are being developed to create more spaces for patients potentially eligible for this treatment.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
SIOG 2024: Updates in haematology
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma
TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia
EHA 2024: Multiple myeloma roundup
Belantamab mafodotin, pomalidomide and dexamethasone shows superior efficacy in RRMM compared to standard of care in 2nd line
Multiple myeloma in a resource constrained setting
